New Imaging Technique for Prostate Cancer Diagnosis Underway in Interim Clinical Trial

A new Phase 1 clinical trial, led by Jonsson Comprehensive Cancer Center, aims to assess the effectiveness of a novel imaging technique using flotufolastat F 18, a radioactive imaging agent, in conjunction with positron emission tomography (PET)/computed tomography (CT) scans to guide targeted prostate biopsies in men with prostate cancer. The trial, currently not open for recruitment, will enroll 30 participants from the USA and be conducted in collaboration with BLUE EARTH DIAGNOSTICS (UNITED KINGDOM). The study seeks to evaluate whether this imaging technique can increase the detection of prostate cancer by providing anatomical information and guidance during a prostate biopsy.

Key Takeaways:

• The clinical trial aims to assess the effectiveness of a new imaging technique using flotufolastat F 18 and PET/CT scans in guiding targeted prostate biopsies.
• The trial will enroll 30 participants from the USA and be conducted by Jonsson Comprehensive Cancer Center in collaboration with BLUE EARTH DIAGNOSTICS (UNITED KINGDOM).
• The study seeks to improve the detection of prostate cancer by providing anatomical information and guidance during a prostate biopsy.
• The investigators aim to determine how often prostate cancer is found when using PSMA PET/CT scan images during a biopsy versus conventional magnetic resonance imaging-guidance.
• The trial's principal investigator is Wayne Brisbane.

Statistics:

• The trial will enroll 30 participants from the USA.
• The study aims to evaluate the effectiveness of a new imaging technique using flotufolastat F 18 and PET/CT scans.

Sources:

• ClinicalTrials.gov
• [Category: Health Care Equipment, Health Care, Partnerships and Alliances, Clinical Trials, Clinical Study, Medical Science, Medicine Research, Biomedical Research, Behavioral Research, Experimentation]